Learn how pharmacists spot systemic mastocytosis sooner—using sensitive KIT testing, WHO/ICC criteria, and smarter referrals to improve outcomes.

Learn how pharmacists spot systemic mastocytosis sooner—using sensitive KIT testing, WHO/ICC criteria, and smarter referrals to improve outcomes.

Led by the moderator, the panelists discussed long-term complications such as osteoporosis, organ involvement, and recurrent anaphylaxis, along with common triggers including NSAIDs, opioids, alcohol, and physical exertion, highlighting symptom journaling as a practical tool for patient education.

Led by the moderator, the expert pharmacists examined the broad differential diagnosis for systemic mastocytosis (SM), including non-clonal mast cell activation syndrome, neuroendocrine tumors, myeloid neoplasms, and cutaneous mastocytosis, alongside the evolving landscape of KIT D816V mutation testing — from allele-specific PCR and digital droplet PCR to next-generation and Sanger sequencing — each with distinct sensitivity trade-offs.

The panelists examined how treatment goals differ between indolent and advanced systemic mastocytosis (SM) — the former focused on symptom control and quality of life, the latter also targeting disease modification to reduce mast cell burden and organ damage — and outlined the pharmacist's role in acute anaphylaxis management, including patient education on epinephrine use and antihistamine dosing.

Led by the moderator, the panelists discussed the rationale for targeting the KIT D816V mutation with tyrosine kinase inhibitors and reviewed six-month and three-year PIONEER trial data showing sustained reductions in symptom burden and improved quality of life with avapritinib in indolent systemic mastocytosis, with minimal treatment discontinuation due to adverse events.

Led by the moderator, the expert pharmacists examined treatment options for advanced systemic mastocytosis (SM), including higher-dose avapritinib, midostaurin for patients without or with unknown KIT mutation status, and cytoreductive agents such as cladribine and interferon for those not responding to or tolerating targeted therapy.

The panelists examined dosing considerations for avapritinib, starting at 25 mg with titration to 50 mg in indolent systemic mastocytosis (SM) compared with 200 mg in advanced disease, as well as midostaurin's 100 mg twice-daily dosing in advanced SM, emphasizing patient counseling that dose adjustments reflect tolerability rather than treatment failure.

Led by the moderator, the panelists discussed how pharmacists integrate the Total Symptom Score into clinical workflows to track symptom burden over time and distinguish drug-related adverse effects, such as fatigue and cognitive changes, from disease-related symptoms.

Led by the moderator, the panelists/expert pharmacists examined common specialty pharmacy and insurance barriers facing patients starting tyrosine kinase inhibitor therapy, sharing proactive strategies such as pre-identifying patient assistance and quick-start programs, securing copay assistance and grant funding, and writing data-driven appeal letters to support payer approvals.